Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Underlying Cirrhosis in the Second-Line Setting of HCC

February 15th 2017

Incorporating Regorafenib in the HCC Treatment Landscape

February 15th 2017

Improving Survival in HCC

February 15th 2017

Dosing Strategies With Sorafenib in HCC

February 15th 2017

HCC: Timing of Locoregional and Systemic Therapies

February 15th 2017

Locoregional Therapy Options in HCC

February 15th 2017

Radiofrequency Ablation and Curative Intent in HCC

February 15th 2017

Resection vs Transplant in HCC: Factors to Consider

February 15th 2017

Liver Transplant Candidacy in HCC

February 15th 2017

Multidisciplinary Approaches in HCC

February 15th 2017

Dr. Kumar on the Safety and Efficacy of Venetoclax in Myeloma

January 24th 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the safety profile and the survival benefits associated with venetoclax in the treatment of patients with multiple myeloma.

Combining and Sequencing BCR-ABL TKIs with Omacetaxine in CML

January 21st 2017

Toxicity for Omacetaxine in CML

January 21st 2017

Experience with Omacetaxine for TKI-Resistant TKI CML

January 21st 2017

Alternative Mechanism for Treatment of Resistant CML

January 21st 2017

Defining Suboptimal Response to BCR-ABL TKI Therapy in CML

January 21st 2017

Dr. Petrylak on Sequencing of Targeted Agents in Bladder Cancer

January 20th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses major targeted agents currently being studied in the treatment of patients with bladder cancer.

Dr. Kris on the Future of Immunotherapy and Targeted Therapy in Lung Cancer

January 4th 2017

Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses what the future holds for the development of immunotherapy and targeted therapy in the treatment of patients with lung cancer.

Melanoma Case Studies Illustrate Factors in Choosing Targeted Therapies

January 2nd 2017

In recent years, advancements in the treatment of patients with metastatic melanoma have proceeded in 2 areas: targeted therapies and immunotherapies.

The Big Picture for 2017: 6 Experts Weigh In

January 1st 2017

Two of the most noteworthy developments in the oncology field during 2016 were the continued expansion of checkpoint blockade immunotherapy agents into more cancer types and the federal government’s plans for funding and remaking the research paradigm.